Seeking Alpha
View as an RSS Feed


View DoctoRx's Articles BY TICKER:
  • Review Of Biotechs (Part 3 Of 3): Focus On Small-Caps; Initiating Coverage Of OPKO
    Editors' Pick  • Yesterday, 2:37 PM OPK 76 Comments
  • Biotech Review (Part 2 Of 3): New Coverage Of Some Mid-Caps With Update On Intercept
    Mon, Aug. 31 ICPT 35 Comments
  • Comments On The Market Correction; Focus On Biotechs: Large Caps
    Editors' Pick  • Wed, Aug. 26 REGN 111 Comments
  • Gilead's Pipeline, Part 3, With Summary Comments
    Editors' Pick  • Mon, Aug. 24 GILD 122 Comments
  • A Review Of Gilead's Pipeline (Part 2): Focus On Zydelig And Lymphoma/CLL Candidates
    Thu, Aug. 20 GILD 76 Comments
  • A Review Of Gilead's Pipeline (Part 1)
    Tue, Aug. 18 GILD 110 Comments
  • Apple Drops, Becomes More Attractive As It Aims For Total Victory Over Android And Windows
    Fri, Aug. 14 AAPL 314 Comments
  • Isis Pharma Stock Drops On Good News: Re-Evaluating The Bull Case
    Thu, Aug. 13 ISIS 64 Comments
  • An Analysis Of Achillion, A Play On Johnson & Johnson's New Efforts In The Hepatitis C Market
     • Thu, Aug. 13 ACHN 40 Comments
  • Shaken, Not Stirred: Is The 'Biotech Bubble' Beginning To Burst?
    Editors' Pick  • Fri, Aug. 7 ICPT 186 Comments
  • Regeneron Aims For $1000 As Its Growth Accelerates Yet Again
    Tue, Aug. 4 REGN 44 Comments
  • A Post-Earnings Review Of Amgen, With Discussion Of The Repatha Launch
    Mon, Aug. 3 AMGN 53 Comments
  • Gilead Beats And Raises: Thinking Through The Future Of Its Business And Its Stock Price
    Wed, Jul. 29 GILD 277 Comments
  • The Importance Of Newly-Released Data For Gilead's HIV Drug Patent Cliff
    Mon, Jul. 27 GILD 77 Comments
  • Biogen Falls Hard: Is It Undervalued Now?
    Mon, Jul. 27 BIIB 55 Comments
  • An Assessment Of Celgene's Deal For Receptos
    Tue, Jul. 21 CELG 43 Comments
  • An Analysis Of Intercept Pharma, An Innovator In Serious Liver Diseases With Unmet Needs
    Editors' Pick  • Wed, Jul. 15 ICPT 63 Comments
  • A Pre-Earnings Look At Gilead Sciences
    Tue, Jul. 14 GILD 247 Comments
  • Apple: Lots Of Smoke (FUD), But What's On Fire Are Earnings And Growth Opportunities
    Fri, Jul. 10 AAPL 207 Comments
  • Biotech At A Fraught Mid-Year: An Overview And Look Ahead
    Thu, Jul. 9 ABBV, ACHN, ADXS 98 Comments
  • Multiple Observations On Celgene's Latest Licensing Deals, And Its Valuation
       • Fri, Jul. 3 CELG 75 Comments
  • Vertex Pharma: Well Positioned To Set New Highs
    Fri, Jun. 26 VRTX 24 Comments
  • Is Biotech Finally In A Bubble?
    Editors' Pick  • Fri, Jun. 19 ABBV, ACHN, ALXN 246 Comments
  • Amgen, Regeneron LDL-Lowering Drugs Provide Major Upside Potential To Their Stocks
    Mon, Jun. 15 AMGN 52 Comments
  • Isis Pharmaceuticals: Another Regeneron (Or Even Better) In The Making?
    Fri, Jun. 12 ISIS 127 Comments
  • Sorrento Therapeutics And L.A.'s Richest Man Ally, Target Celgene's Blockbuster Abraxane
    Mon, Jun. 8 CELG 41 Comments
  • Portola's Lymphoma Drug Looks Good At ASCO
    Tue, Jun. 2 PTLA 25 Comments
  • Why I Bought The Dip In Amgen: Focus On Repatha And Other Aspects Of The Pipeline
    Editors' Pick  • Tue, Jun. 2 AMGN 36 Comments
  • Why I Bought The Dips In Both Gilead And Achillion Today
    Editors' Pick  • Wed, May 20 ACHN, GILD 178 Comments
  • A Critique Of Carl Icahn's Apple Fair Value Revaluation To $240 Per Share
    Tue, May 19 AAPL 109 Comments
  • Regeneron Beats, Raises And Accelerates Its Late-Stage Product Development
    Editors' Pick  • Mon, May 11 REGN 31 Comments
  • Celgene's Plan For Life After Revlimid, With Discussion Of Q1 Earnings
    Mon, May 4 CELG 33 Comments